Contact this trialFirst, we need to learn more about you.
Alkylating Agent
Veliparib + Temozolomide for Leukemia
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial is testing the side effects and best dose of giving veliparib with temozolomide to treat leukemia. Veliparib may stop cancer cell growth by blocking enzymes needed for cell growth. Temozolomide may kill or stop cancer cells from dividing. Giving veliparib with temozolomide may kill more cancer cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service